Esperion Therapeutics (ESPR) Times Interest Earned (2012 - 2026)
Esperion Therapeutics (ESPR) posted Times Interest Earned of -$0.33 for Q1 2026, down 108.83% on a QoQ basis from $3.77 in Q4 2025, and up 70.77% year-over-year from -$0.19 in Q1 2025.
Esperion Therapeutics (ESPR) Times Interest Earned (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Times Interest Earned history runs 15 years deep, the most recent figure standing at -$0.33 for Q1 2026.
- Quarterly Times Interest Earned rose 70.77% year-over-year to -$0.33 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.89 (up 262.69% YoY) and the FY2025 annual result came in at $0.14, up 9.73% from the prior year.
- Times Interest Earned was -$0.33 for Q1 2026 at Esperion Therapeutics, down from $3.77 in the prior quarter.
- Across five years, Times Interest Earned topped out at $5.15 in Q1 2024 and bottomed at -$3.67 in Q2 2022.
- A 5-year average of -$1.0 and a median of -$1.14 in 2025 frame the typical range for Times Interest Earned.
- Peak annual rise in Times Interest Earned reached 2200.52% in 2025, while the deepest fall reached 122.07% in 2025.
- Esperion Therapeutics' Times Interest Earned stood at -$2.97 in 2022, then grew by 5.16% to -$2.81 in 2023, then surged by 93.63% to -$0.18 in 2024, then soared by 2200.52% to $3.77 in 2025, then tumbled by 108.83% to -$0.33 in 2026.
- Business Quant data shows ESPR's Times Interest Earned at -$0.33 in Q1 2026, $3.77 in Q4 2025, and -$0.45 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.33 |
| Dec 31, 2025 | 3.77 |
| Sep 30, 2025 | -0.45 |
| Jun 30, 2025 | 0.35 |
| Mar 31, 2025 | -1.14 |
| Dec 31, 2024 | -0.18 |
| Sep 30, 2024 | -1.06 |
| Jun 30, 2024 | 0.19 |
| Mar 31, 2024 | 5.15 |
| Dec 31, 2023 | -2.81 |
| Sep 30, 2023 | -1.84 |
| Jun 30, 2023 | -2.55 |
| Mar 31, 2023 | -3.38 |
| Dec 31, 2022 | -2.97 |
| Sep 30, 2022 | -2.94 |
| Jun 30, 2022 | -3.67 |
| Mar 31, 2022 | -3.06 |
| Dec 31, 2021 | -4.14 |
| Sep 30, 2021 | -4.08 |
| Jun 30, 2021 | -2.92 |